Clinical Trial Detail

NCT ID NCT02054806
Title Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

Advanced Solid Tumor

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.